|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5340 EUR | -4.13% |
|
+4.01% | -64.52% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 50.72M | |
| 2.61% | 2.72% | 40.81x | 6.22x | 5.38x | 20.78x | 27.88x | 322B | |
| 1.61% | 1.67% | 24.53x | 2.06x | 3.35x | 11.92x | 19.67x | 71.8B | |
| 2.54% | 2.72% | 17.5x | 1.51x | 2.24x | 7.66x | 9.17x | 8.64B | |
| -.--% | -.--% | 20.17x | 5.36x | 5.67x | 16.07x | 16.74x | 4.08B | |
| 0.79% | 0.8% | 38.6x | 2.33x | 2.21x | 27.72x | 41.35x | 3.61B | |
| -.--% | -.--% | 104.65x | - | - | - | - | 2.7B | |
| 3.92% | 3.32% | 16.96x | 0.78x | 1.43x | 25.66x | 50.32x | 1.1B | |
| Average | 1.64% | 1.6% | 37.60x | 3.04x | 3.38x | 18.30x | 27.52x | 51.74B | |
| Weighted average by Cap. | 2.38% | 2.48% | 37.63x | 5.34x | 4.92x | 18.98x | 26.12x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
